Core Insights - DBV Technologies reported its financial results for the full year 2025, focusing on advancing its clinical development programs and preparing for the commercialization of the VIASKIN® Peanut Patch [2][3] Financial Performance - Operating income for 2025 was $5.6 million, an increase from $4.2 million in 2024, attributed to higher eligible activities for the French Research Tax Credit [11] - Research and Development (R&D) expenses rose by $27.3 million in 2025 compared to 2024, reflecting increased investment in clinical programs [12] - Selling, General and Administrative (SG&A) expenses increased by $4.6 million in 2025, primarily due to market research activities and operational enhancements for the VIASKIN® Peanut Patch launch [12] - The net loss for 2025 was $147.0 million, compared to $113.9 million in 2024, with a net loss per share of $1.05 for 2025 [13] - Cash and cash equivalents stood at $194 million as of December 31, 2025, a significant increase from $32.5 million in 2024, with net cash used for operating activities at $121.2 million [14] Operational Highlights - The company advanced its clinical development programs for the VIASKIN® Peanut Patch in peanut-allergic toddlers and children, reporting positive topline results from the Phase 3 VITESSE trial [8][10] - A supplemental safety study, COMFORT Toddlers, was initiated for peanut-allergic toddlers aged 1 to 3 years [8] - The company appointed new executives to strengthen its leadership team in preparation for the potential commercialization of the VIASKIN® Peanut Patch [9] Anticipated Events - The company plans to submit a Biologics License Application (BLA) for children aged 4 to 7 years in the first half of 2026, with a potential for Priority Review [15] - Completion of enrollment for the COMFORT Toddlers safety study is expected, with topline results anticipated [15] - A BLA submission for 1-3 year olds is anticipated in the second half of 2026 under an Accelerated Approval Pathway [15]

Core Insights - DBV Technologies will present additional data from the VITESSE Phase 3 study of the VIASKIN® Peanut Patch for children aged 4-7 at the AAAAI 2026 Annual Meeting in Philadelphia from February 27 to March 2, 2026 [1] - The company will host a product theater featuring allergists discussing the potential of epicutaneous immunotherapy (EPIT) in food allergy treatment and the impact of early intervention [2] Company Overview - DBV Technologies is a late-stage biopharmaceutical company focused on developing treatments for food allergies and other immunologic conditions with significant unmet medical needs [4] - The company is investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which can cause severe reactions including anaphylaxis [4] - The VIASKIN® patch aims to introduce microgram amounts of biologically active compounds to the immune system through intact skin, representing a non-invasive treatment approach [4] Event Details - The oral abstract presentation titled "VITESSE Phase 3 Study: Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children 4 Through 7 Years of Age" will take place on February 28, 2026 [3][6] - The product theater session titled "Epicutaneous Immunotherapy (EPIT): Shaping the Future of Pediatric Food Allergy Treatment" will also occur on February 28, 2026 [3][6] - DBV will exhibit at booth 1527 at the AAAAI exhibit hall to provide more information about epicutaneous immunotherapy and the VIASKIN® Peanut Patch [3]